PK/PD study of Pembrolizumab
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000036606
- Lead Sponsor
- ational Cancer Center Research Institute Division of Molecular Pharmacology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who have treated with Pembrolizumab 2)Patients who denied to collect sample 3)Patients whose attending doctor consider as inappropriate for this study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacokinetics of pembrolizumab
- Secondary Outcome Measures
Name Time Method 1)Responce rate 2)Disease control rate 3)Progression free survival 4)Overall survival 5)Adverse event 6)PK/PD/PGx 7)Biomarker